A previous study by Yu et al. showed that PRPM downregulated AMPK/SREBP-1 in a NAFLD zebrafish model [34], so we also explored the actions of PRPM on the de novo lipogenesis pathway (DNL) (Figure 6). Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.